Healthcare company GlaxoSmithKline has moved 7.8% so far today on a volume of 25,643,833, compared to its average of 6,094,646. In contrast, the S&P 500 index moved -1.9%
GSK trades -14.06% away from its average analyst target price of $44.11 per share. The 3 analysts following the stock have set target prices ranging from $33 to $63.75, and on average have given Series([], ) a rating of hold.
Anyone interested in buying GSK should be aware of the facts below:
-
GSK's Graham number (a purchase price with a built-in margin of safety) is $16.54, which is 129.2% away from its current price
-
GlaxoSmithKline has moved -17.0% over the last year, and the S&P 500 logged a change of -14.7%
-
Based on its trailing earning per share of 2.68, GSK has a trailing 12 month Price to Earnings (P/E) ratio of 14.1 while the S&P 500 average is 15.97
-
GSK has a forward P/E ratio of 10.4 based on its forward 12 month price to earnings (Eps) is $3.66 per share
-
The company has a price to earnings growth (PEG) ratio of 0.91 -- a number near or below 1 signifying that GSK is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 8.4 compared to its sector average of 4.07
-
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
-
Based in Brentford, the company has 90,096 full time employees and a market cap of $77,097,566,208. GlaxoSmithKline currently returns an annual dividend yield of 2.2%.